Will Advisory Committee Review Vindicate Pfizer’s Vyndaqel?
This article was originally published in The Pink Sheet Daily
Pfizer’s orphan drug tafamidis will be reviewed by FDA’s Peripheral and Central Nervous System Drugs Advisory Committee in May. The scheduling of a panel during a priority review is some indication FDA has concern, but the panels of outside experts are generally receptive to rare disease treatments.
You may also be interested in...
The company says a data formatting issue was the reason FDA declined to accept the supplemental application for alemtuzumab for relapsing multiple sclerosis.
Pfizer gained the therapy to treat a rare genetic neurologic disorder in its 2010 acquisition of folded protein company FoldRx.
FDA may be seeking more safety data before approving of Uplyso, a plant cell-derived enzyme replacement therapy.